CATALYSTYahoo Finance • 1d ago
Amylyx Pharmaceuticals And 2 More Quality Growth StocksYahoo Finance report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
Why AMLX Stock dropped -2.84% Today — RQD Quant Desk Flash
$28.04 -2.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $27.84
Amylyx Pharmaceuticals Inc. (AMLX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $3.62B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AMLX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AMLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $28.04 (-2.84% 1D, market cap $3.62B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, AMLX ranks #480 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AMLX compare to XENE and OGN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMLX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XENE (Xenon Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B) and OGN (Organon & Co.) posts a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AMLX?
▼
Per AMLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001658551), Amylyx Pharmaceuticals Inc. generated $429.2M in revenue (+391.3% YoY), -$144.7M in net income, and -$123.5M in free cash flow against $332.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $27.84 (-0.70%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-8.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AMLX)Realized 20D OHLCV Swing Band: ±9.6%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY AMLX SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (26% of score)
20D Institutional Volume Accumulation (±9.6% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$26.85+7.2% Next Q
31
Q2 (-2Q)Grade E$28.77-1.6% Next Q
34
Q3 (-1Q)Grade E$28.30-0.9% Next Q
36
CurrentGrade D-$28.04-7.6% Hist 90D α
39
Trajectory: E (31) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AMLX Turnaround Squeeze
While AMLX currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($30.51) and Max Pain ($29.44) forces dealer call-delta covering toward $43.20.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AMLX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AMLX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AMLX Stock dropped -2.84% Today — RQD Quant Desk Flash
Amylyx Pharmaceuticals Inc. (AMLX) dropped -2.84% to $28.04, trading at 57% of its 52-week range ($10.83 – $41.14). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 57% of its 52-week range ($10.83 – $41.14) with RSI-14 at 51.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.6% around $28.04 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live AMLX Headlines & Catalysts
MARKET WIRETradingView • 1d ago
Amylyx Pharmaceuticals, Inc. Estimates – NASDAQ:AMLXTradingView report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Amylyx Pharmaceuticals (NasdaqGS:AMLX) Stock Forecast & Analyst PredictionsSimply Wall St report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A live call will cover Amylyx's third-quarter results on Nov. 5 at 8 a.m. ET.Stock Titan report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Amylyx Pharma Q2 2026 Earnings Call TranscriptBenzinga report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingView • 1d ago
Amylyx Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $43, Implies 59% UpsideTradingView report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Amylyx Pharmaceuticals (AMLX) Short Interest & Short Float | Updated Oct 2026MarketBeat report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Will Phase 3 Trial Data Change Amylyx Pharmaceuticals Stock NarrativeSimply Wall St report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 8d ago
Can Corcept Therapeutics Stock Rally 40% After This Dip?For questions about this article or underlying research, email help@trefis.com.
CATALYSTBenzinga • 19d ago
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AMLX)
- ✓Walkthrough of AMLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AMLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +70.35%🛡️ HOLDING TREND SUPPORT
2026-11-03O $28.68H $28.86L $28.04C $28.04VOL 989.5K
RES: $36.91SUP: $27.50SMA50: $30.51SMA200: $20.23
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AMLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +391.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on AMLX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AMLX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AMLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AMLX)
Health Care Rank #480 of 1015
⚔️ XENE vs AMLX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AMLX vs. XENE, OGN, IRON, ACAD)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Amylyx Pharmaceuticals Inc. (AMLX) ranks #480 by composite RQD confidence (39/100, grade D-) and #190 by equity capitalization ($3.62B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. OGN currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with AMLX at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AMLX
ACTIVE
Amylyx Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | -2.84% | $3.62B | Benchmark Subject |
| XENE Xenon Pharmaceuticals Inc. | D- | 37/100 | — | — | -35.0% | +0.56% | $3.62B | /xene-vs-amlx → |
| OGN Organon & Co. | B- | 70/100 | 19.4x | 53.3% | 24.9% | -0.14% | $3.63B | /ogn-vs-amlx → |
| IRON Disc Medicine Inc. | D+ | 54/100 | — | — | -27.5% | -2.75% | $3.59B | /iron-vs-amlx → |
| ACAD ACADIA Pharmaceuticals Inc. | D | 49/100 | 9.1x | 91.7% | 7.9% | -0.58% | $3.55B | /acad-vs-amlx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001658551 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Amylyx Pharmaceuticals Inc. (AMLX) reported GAAP revenue of $429.2M (+391.3% vs. FY2024 revenue of $87.4M , and +12.7% cumulative change since FY2023) , GAAP net income of -$144.7M, operating cash flow of -$123.3M, and free cash flow of -$123.5M (+26.4% YoY). On the balance sheet, AMLX closed FY2025 with $332.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $429.2M | -$144.7M | -$123.3M | -$123.5M | $332.6M | — |
| FY2024 (FY) | 2024-12-31 | $87.4M | -$301.7M | -$167.6M | -$167.8M | $193.6M | — |
| FY2023 (FY) | 2023-12-31 | $380.8M | $49.3M | $11.9M | $11.9M | — | — |
3. AMLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AMLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $28.04 (-2.84% 1D, market cap $3.62B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, AMLX ranks #480 in composite RQD confidence.
How does AMLX compare to XENE and OGN in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AMLX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XENE (Xenon Pharmaceuticals Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $3.62B) and OGN (Organon & Co.) posts a B- grade (70/100 RQD, P/E 19.4x, ROIC 24.9%, cap $3.63B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AMLX?
Per AMLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001658551), Amylyx Pharmaceuticals Inc. generated $429.2M in revenue (+391.3% YoY), -$144.7M in net income, and -$123.5M in free cash flow against $332.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AMLX trading relative to its 50-day, 200-day, and 52-week technical levels?
AMLX last traded at $28.04 (-2.84% on volume of 1,161,875 shares), positioning the stock -8.10% below its 50-day simple moving average ($30.51) and +38.61% above its 200-day simple moving average ($20.23). Across its 52-week range of $10.83 to $41.14, AMLX sits at the 56.8% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($25.35 to $30.73).
ROARABLE RATING BRIEF • RQD 39/100 (D-)
✓ SEC XBRL & RQD VERIFIED
AMLX — Amylyx Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Amylyx Pharmaceuticals Inc. (AMLX) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $28.04 (-2.84% 1D, market capitalization $3.62B).
- Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -3.43%.
- Whale 13F & Options Flow (10/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Amylyx Pharmaceuticals Inc. (AMLX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The company carries a market capitalization of $3.6B per the market data. Reported revenue was $380.8M for FY 2023, $87.4M for FY 2024, and — for FY 2025. — describes the company's specific products, customers, or revenue model.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Amylyx Pharmaceuticals Inc. (AMLX) reported $429.2M in annual revenue (up from $87.4M in FY2024, +391.3% YoY) and -$144.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($380.8M revenue, $49.3M net income) through FY2025, AMLX scaled operating cash flow to -$123.3M and free cash flow to -$123.5M, backed by $332.6M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.43% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $10.83 – $41.14 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Sector and industry classifications are Health Care and Biotechnology: Pharmaceutical Preparations, but no sector correlation data is provided. No 2nd-order bottlenecks are identified in the source data.
- Key Question #1: Can AMLX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $429.2M and free cash flow of -$123.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is AMLX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
AMLX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Amylyx Pharmaceuticals Inc. (AMLX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 1d ago
Amylyx Pharmaceuticals And 2 More Quality Growth Stocks Yahoo Finance report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Amylyx Pharmaceuticals, Inc. Estimates – NASDAQ:AMLX TradingView report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Amylyx Pharmaceuticals (NasdaqGS:AMLX) Stock Forecast & Analyst Predictions Simply Wall St report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A live call will cover Amylyx's third-quarter results on Nov. 5 at 8 a.m. ET. Stock Titan report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Amylyx Pharma Q2 2026 Earnings Call Transcript Benzinga report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingView • 1d ago
Amylyx Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $43, Implies 59% Upside TradingView report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Amylyx Pharmaceuticals (AMLX) Short Interest & Short Float | Updated Oct 2026 MarketBeat report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Will Phase 3 Trial Data Change Amylyx Pharmaceuticals Stock Narrative Simply Wall St report covering Amylyx Pharmaceuticals Inc. (AMLX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
AMLX Bull vs. Bear Conversation Board — What's Your Call at $28.04?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AMLX 🐻 33% BEARISH CONVICTION
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH
🎯 Target: $35.50 (+23.0%)
📌 Pinned Debate A reported 12-month price target raised to $43 implies 59% upside from the current price, and reported cash increased to $226.7M in FY
The street is overcomplicating Amylyx Pharmaceuticals Inc. (AMLX). A reported 12-month price target raised to $43 implies 59% upside from the current price, and reported cash increased to $226.7M in FY 2025.. With an RQD score of 39/100 (D-) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $31.17.
SectorRotator 🐂 BULL
@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH
🎯 Target: $23.38 (-19.0%)
Spot @ $28.86 Reported net income fell to -$144.7M in FY 2025 with ROIC at -35% and FCF yield at -3.43%, while revenue dropped to $0.0M.
I respect the product at Amylyx Pharmaceuticals Inc., but the stock at $28.86 is a different story. Reported net income fell to -$144.7M in FY 2025 with ROIC at -35% and FCF yield at -3.43%, while revenue dropped to $0.0M.. FCF yield is -3.43% and RQD sits at 39/100 (D-) — why pay up here when you can wait for next quarter's numbers?